Precision BioSciences Enters Into Private Convertible Note Financing

March 11, 2019 11:00 UTC

Capital Generated Since Inception Now Exceeds $300 Million

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences (“Precision” or the “Company”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced that it has entered into an agreement for the issuance and sale of convertible promissory notes in a private placement transaction in the aggregate principal amount of approximately $40 million, which will bring the Company’s total capital generated in the last year to over $150 million and total funding since inception to over $300 million. Contributors to this financing were largely first-time investors in the Company.

Investors in Precision now include ArrowMark Partners, Franklin Templeton, Cowen Healthcare Investments, venBio, F-Prime, RA Capital Management, Brace Pharma Capital, Pontifax AgTech, OCV Partners, DSAM, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Laurion Capital Management, Vivo Capital, Lilly Asia Ventures, Alexandria Venture Investments, Ridgeback Capital, Ditch Plains Capital Management, Agent Capital, entities affiliated with Leerink Partners, Amgen Ventures, Osage University Partners, DUMAC and the Longevity Fund.

About Precision BioSciences

Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, “ARCUS.” Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For additional information, please visit


Precision BioSciences:
Heather King
+1 919-314-5512

Source: Precision BioSciences

Back to news